Canadian drug firms have stopped distributing ranitidine antacid products due to contamination with a probable carcinogen while the author of a citizen petition to the the US Food and Drug Administration argues to withdraw the ingredient globally.
In a 17 September statement, Health Canada said it took the “interim, precautionary measure” of asking companies not to distribute additional supplies of the H2 blockers while the agency gathers information from companies and works with international regulators
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?